期刊文献+

蛋白转化酶枯草溶菌素9对诊断冠状动脉狭窄的价值研究

原文传递
导出
摘要 目的:分析蛋白转化酶枯草溶菌素9(PCSK 9)对诊断冠状动脉狭窄的价值。方法:选择经冠状动脉造影检查明确存在冠状动脉狭窄60例,按照狭窄程度分为轻度组、中度组及重度组。比较3组PCSK 9、TG、LDL-C及HDL-C水平,并分析PCSK 9与血脂水平及狭窄程度的相关性,评估PCSK 9对冠状动脉狭窄的诊断价值。结果:重度狭窄组PCSK 9水平显著或非常显著高于轻度及中度狭窄组(P<0.05,P<0.01);重度狭窄组TG、LDL-C水平显著高于轻度狭窄组,HDL-C水平显著低于轻度狭窄组(P<0.05)。相关分析结果显示,PCSK 9水平与TG、LDL-C及冠脉狭窄程度呈显著正相关,与HDL-C呈显著负相关(P<0.05)。结论:PCSK 9水平增高可能加重脂质代谢紊乱及冠状动脉狭窄程度;检测PCSK 9对诊断冠状动脉狭窄有重要参考价值。
出处 《人民军医》 2015年第6期679-680,共2页 People's Military Surgeon
  • 相关文献

参考文献10

  • 1Hofflaines A J, Jen CH, Leary JA, et al. Tyrosylprotein sulfotransferase-2 expression is required for sulfation of RNase 9 and Mfge8 in vivo[J]. J t3iol Chem,2009,284(5):3095-3105. 被引量:1
  • 2Seidah NG,Benjannet S,Wickham L,et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1) Liver regeneration and neuronal differentiation [J]. Proc Natl Acad Sci USA, 2003,100(3) : 928-933. 被引量:1
  • 3BenjannetS, Rhainds D, Essalmani R, et al. NARC-1/PCSK9 and its natural muta nts..Zymogen cleavage and effects on the low density li- poprote in (LDL) recep torand LDL cholesterol [ J ]. J Biol Chem, 2004,279(47) .. 48865-48875. 被引量:1
  • 4Hunt SC, Hopkins PN,Bulka K,et al. Genetic localization to chromo- melp 32 of the third locus for familial hypercholesterolemia in all tall kindred [J]. Arterioscler Thromb Vasc Biol, 2000, 20 (4): 1089-1093. 被引量:1
  • 5Cunningham D, Danley DE, Geoghegan KF, et al. Structuraland bio- physical studies of PCSK9 and its mutants linked to familial hyper- cholesterolemia[J]. Nat Struct Mol Biol,2007,14(5):413-419. 被引量:1
  • 6Poirler S,Mayer G,Poupom V. Dissection of the endogenous eellufar pathways of PCSKg-induced low density/ipoprotein receptor degrada- tion:Evidence for an intracellular route[J]. J Biol Chem, 2009, 221 (45) :28856 28864. 被引量:1
  • 7Dubuc G,Chamberland A,Wassef H,et al. Statins upreguulate PC- SKg, the gene encoding the proprotein eonvertase neuralapoptosis'- regulated convertase-1 implicated in familial hupeccholesternlemia [J]. Arterioscler Thromb Vase Binl,2004,34(16) : 1454-1459. 被引量:1
  • 8Duhuc G,Tremblay M, Pare G. A new method fur measurement of total plasma PSCK9: Clinical applications[J]. J Lipid Res, 2010, 21 (3) :140-149. 被引量:1
  • 9Seidah NG, Abifadel M. PCSK9 as a therapeutic target of dyslipidemia D]. Expert ()pin Therapeutic Targets ,2009 : 14(1) : 19-28. 被引量:1
  • 10Lakoski SG, LaSace TA, Cohen JC. Genetic and metabolic determinant of plasma PCSK9 levels[J]. J Clin Endocrinol Metab, 2009,42(7) :2537-2543. 被引量:1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部